Viscosupplementation Devices Market Summary

• The Global Viscosupplementation Devices Market is expected to increase from USD 4.08 billion in 2023 to USD 6.43 billion by 2030, reflecting strong and sustained growth.
• The Global Viscosupplementation Devices Market is growing at a CAGR of 7.94% during the forecast period from 2024 to 2030.

Viscosupplementation Devices Market Trends & Insights

• The leading Viscosupplementation Devices Companies such as Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Sanofi, Smith & Nephew, Ferring B.V., Lifecore Biomedical, LLC, LG Chem, Fidia Farmaceutici S.p.A., OrthogenRx, Bioventus, DePuy Synthes (Johnson & Johnson), Vivacy, APTISSEN, KiOmed Pharma, BioPolymer GmbH & Co KG, ALBOMED® GmbH, Juniper Biologics, Ono Pharmaceutical Co., Ltd., CarthroniX, Zimmer Biomet, and others.
• North America is expected to account for the highest proportion of the viscosupplementation devices market in 2023 out of all regions North America is expected to dominate the overall viscosupplementation devices market during the forecast period.
• In the product type of device segment of the viscosupplementation devices market, a single injection is projected to hold a considerable market share in 2023.

Viscosupplementation Devices Market Size and Forecast

• 2023 Market Size: - USD 4.08 billion
• 2030 Projected Market Size: USD 6.43 Billion
• Growth Rate (2024-2030): CAGR 7.94%
• Largest Market: North America
• Fastest Growing Market: Asia-Pacific

Factors Impacting the Viscosupplementation Devices Market Growth

• Rising Prevalence of Osteoarthritis

One of the primary drivers of the viscosupplementation devices market is the growing prevalence of osteoarthritis globally. As the aging population increases, the number of individuals affected by degenerative joint diseases is also rising. This growing patient pool is driving demand for viscosupplementation as an effective treatment option to relieve pain and improve mobility.

• Increasing Geriatric Population

The rapidly expanding elderly population is contributing significantly to market growth. Older individuals are more prone to joint-related disorders such as knee osteoarthritis, which makes them prime candidates for viscosupplementation therapies. This demographic trend is anticipated to drive the continuous adoption of viscosupplementation devices.

• Technological Advancements in Viscosupplementation Devices

Continuous advancements in viscosupplementation devices, including improved precision, delivery mechanisms, and patient safety, are fueling adoption. Enhanced hyaluronic acid formulations and device innovations make the therapy more effective and convenient, boosting market demand.

Viscosupplementation Devices Market by Product Type (Single Injection, Three Injections, and Five Injections), End-User (Hospitals, Orthopedic Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising prevalence of osteoarthritis, increase in demand for non-surgical treatment, rising advancement in hyaluronic acid-based products, and increase in product launches and product approvals across the globe.

The viscosupplementation devices market was valued at USD 4.08 billion in 2023, growing at a CAGR of 7.94% during the forecast period from 2024 to 2030, to reach USD 6.43 billion by 2030. The rising prevalence of osteoarthritis drives an increased demand for effective treatments, as more individuals seek relief from joint pain and improved mobility. Alongside this, there is a growing preference for non-surgical treatments, making viscosupplementation an appealing option compared to invasive procedures. Technological advancements in hyaluronic acid-based products enhance their effectiveness and safety, leading to greater adoption and improved patient outcomes. Additionally, the surge in product launches and approvals globally expands the availability and variety of viscosupplementation options, making these treatments more accessible to a broader audience. Collectively, these factors address the increasing need for joint pain management, bolster consumer confidence in new therapies, and drive the market forward during the forecast period from 2024 to 2030.

Viscosupplementation Devices Market Dynamics

According to the recent data provided by Global Burden of Disease (2023), by 2050, nearly one billion people are projected to have osteoarthritis, with the most common areas affected being the knees and hips. Specifically, osteoarthritis of the knee is expected to increase by 74.9%, osteoarthritis of the hand by 48.6%, osteoarthritis of the hip by 78.6%, and osteoarthritis in other areas, such as the elbow and shoulder, by 95.1%. Thus, the demand for viscosupplementation devices is set to surge because of the rising prevalence of osteoarthritis and the corresponding need to alleviate chronic pain, which presents a substantial opportunity for the development and adoption of advanced pain management technologies. As more individuals seek relief from the debilitating effects of osteoarthritis, the market for viscosupplementation devices is poised for significant growth and innovation. Viscosupplementation devices, which involve injecting hyaluronic acid into the affected joints to enhance lubrication and cushion, offer a non-surgical solution to alleviate pain and improve joint function thereby boosting the market.

Moreover, the frequent strategic innovations in product development activities by leading market players to address the widespread issue of osteoarthritis are significantly propelling market growth on a global scale. For instance, in December 2023, Bioventus Inc., a global leader in active healing innovations, announced that it had signed a nationwide contract with Aetna™ Medicare Advantage plans. Over 3 million Aetna™ Medicare Advantage plan members were able to access DUROLANE for treating knee osteoarthritis (OA) pain from January 2024. DUROLANE is a single-injection hyaluronic acid (HA) treatment for joints, and it was one of two single-injection hyaluronic acid-based products included in the contract.

Additionally, recent advancements in hyaluronic acid-based products for osteoarthritis (OA) have focused on improving efficacy, extending the duration of relief, and enhancing patient outcomes. Modern HA formulations often use cross-linking technology to create more stable and longer-lasting products. Cross-linked hyaluronic acid provides improved viscosupplementation by forming a gel-like substance that more effectively mimics natural synovial fluid. For example, Durolane, a single-injection hyaluronic acid-based product, uses a cross-linked hyaluronic acid formulation to offer extended relief from knee OA symptoms.

Thus, the factors mentioned above are likely to boost the market of Viscosupplementation Devices during the forecasted period. Additionally, Cingal combines hyaluronic acid with a corticosteroid to provide both lubrication and anti-inflammatory effects, potentially offering superior relief compared to HA alone. These advancements in HA-based products for osteoarthritis reflect a commitment to improving patient outcomes through more effective, long-lasting, and tailored treatment options, thereby escalating the overall market of viscosupplementation devices across the globe.

However, several alternatives to viscosupplementation devices, such as pain medication, physical therapy, Platelet-Rich Plasma Therapy, and others, and the injection-related discomfort and infection to bones may limit their adoption during the forecasted period.

Viscosupplementation Devices Market Segment Analysis

Viscosupplementation Devices Market by Product Type (Single Injection, Three Injections, and Five Injections), End-User (Hospitals, Orthopedic Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type of device segment of the viscosupplementation devices market, a single injection is projected to hold a considerable market share in 2023. Single-injection viscosupplementation devices are significantly boosting the overall market for these treatments by offering several key advantages that appeal to both patients and healthcare providers. Unlike traditional viscosupplementation therapies, which often require multiple injections over several weeks, single-injection products provide a convenient and effective alternative. This innovation simplifies the treatment process, reducing the number of office visits required and enhancing patient compliance. Single-injection products, such as Durolane and Cingal, utilize advanced hyaluronic acid formulations that are designed to provide extended relief from osteoarthritis symptoms with just one administration. These products are formulated to be long-lasting, with the ability to offer relief for up to six months or more, which contrasts with the shorter duration of relief provided by multiple injection regimens. 

Furthermore, the enhanced efficacy and longer duration of relief from single-injection devices can contribute to better patient outcomes, making these products a compelling choice for managing joint pain. As a result, the market for viscosupplementation devices is experiencing growth driven by the increasing demand for simplified and effective treatment options that align with modern patient preferences and healthcare efficiencies. The success and positive reception of single-injection devices reflect a broader trend towards innovations that improve treatment convenience, effectiveness, and accessibility, further propelling the expansion of the viscosupplementation market.

Moreover, the product launch of various single-injection devices for the treatment of osteoarthritis is also expected to surge segment growth. For instance, in August 2022, Seikagaku announced the launch of HyLink®, an intra-articular single injection viscosupplement for the treatment of knee osteoarthritis in Taiwan.

Therefore, owing to the above-mentioned factors, the single injection devices category is expected to generate considerable revenue, thereby pushing the overall growth of the global viscosupplementation devices market during the forecast period.

North America is expected to dominate the overall Viscosupplementation Devices market:

North America is expected to account for the highest proportion of the viscosupplementation devices market in 2023, out of all regions North America is expected to dominate the overall viscosupplementation devices market during the forecast period. The growing prevalence of osteoarthritis and the increase in geriatric population, in the region is anticipated to boost the demand for viscosupplementation devices during the forecasted period across the region. Additionally, recent product approval and launches by the companies actively manufacturing viscosupplementation devices will also contribute to the market growth. Moreover, increasing government initiatives further propels the market of viscosupplementation devices by creating awareness programs, and other activities across the region.

Additionally, as per the recent data provided by the Centre for Disease Control and Prevention, in 2022, the age-adjusted prevalence of diagnosed arthritis among adults aged 18 and older was 18.9%. Women were more likely to have arthritis, with a prevalence of 21.5%, compared to men at 16.1%. Arthritis prevalence increased with age, ranging from 3.6% in adults aged 18–34 to 53.9% in those aged 75 and older. This progressive increase highlighted the significant impact of age on arthritis rates across the adult population.

Arthritis is linked with pain in joints. The increasing incidence of arthritis creates a larger patient population seeking relief from joint pain and stiffness. As more individuals are diagnosed with arthritis, there is a greater need for therapeutic options that can address these symptoms effectively. Furthermore, many patients prefer non-surgical treatments over invasive procedures. Viscosupplementation offers a minimally invasive solution that can be administered with a simple injection, making it an attractive option for those looking to avoid surgery thereby escalating the overall market of viscosupplementation devices across the region.

Furthermore, as per the recent data provided by the Population Reference Bureau (2024), the number of Americans ages 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050. As per the World Health Organization (2023), with aging populations, the prevalence of osteoarthritis is expected to continue to increase globally.

Additionally, the awareness programs in the United States aimed at addressing chronic pain in joints focus on education, prevention, and early detection also boosts the market of viscosupplementation devices across the region as public awareness campaigns educate individuals about the importance of regular screenings and preventive measures. For example, September is designated as Pain Awareness Month in the United States, during which various organizations, including the National Institute of Health (NIH), participate and promote awareness through campaigns, events, and educational materials. These efforts emphasize the importance of managing chronic pain.

Furthermore, product approval across the region further boosts the market of cardiovascular equipment. For instance, in April 2023 Anika Therapeutics, Inc., a company focused on early intervention orthopedics, announced that it had received additional FDA 510(k) clearance for its Tactoset Injectable Bone Substitute. This new clearance allowed Tactoset to be used with autologous bone marrow aspirate (BMA), which helps with tissue regeneration in musculoskeletal injuries. This expansion increased Tactoset’s commercial reach by allowing it to treat bone defects such as osteoporotic bone, cysts, and insufficiency fractures. 

Therefore, the above-mentioned factors are expected to bolster the growth of the viscosupplementation devices market in North America during the forecast period.

Viscosupplementation Devices Companies

Some of the key market players operating in the viscosupplementation devices market include Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Sanofi, Smith & Nephew, Ferring B.V., Lifecore Biomedical, LLC, LG Chem, Fidia Farmaceutici S.p.A., OrthogenRx, Bioventus, DePuy Synthes (Johnson & Johnson), Vivacy, APTISSEN, KiOmed Pharma, BioPolymer GmbH & Co KG, ALBOMED® GmbH, Juniper Biologics, Ono Pharmaceutical Co., Ltd., CarthroniX, Zimmer Biomet, and others.

Recent Developmental Activities in the Viscosupplementation Devices Market:

• In July 2024, Anika announced the full market release of the Integrity™ Implant System, a regenerative hyaluronic acid-based scaffold used for repairing rotator cuff and other tendon injuries.
• In January 2023, CarthroniX received a $5.0 million grant from the US Department of Defense to fund the planning phase and Phase I/IIA of a clinical study on CX-011. This study aimed to assess CX-011 for pain relief, increased function, and potential disease-modifying treatment for knee osteoarthritis.
• In January 2022, Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare commercially launched NeoVisc+ 2 mL and NeoVisc ONE 4 mL in Canada for the treatment and improvement of joint functionality and pain in patients suffering from degenerative or mechanical arthropathy of the knees. 

Key Takeaways from the Viscosupplementation Devices Market Report Study

• Viscosupplementation Devices Market Size analysis for the current size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the viscosupplementation devices market.
• Various opportunities available for the other competitors in the viscosupplementation devices market space.
• What are the top-performing segments in 2023? How will these segments perform in 2030?
• Which are the top-performing regions and countries in the current viscosupplementation devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the viscosupplementation devices market growth in the coming future?

Target Audience who can benefit from the Viscosupplementation Devices Market Report Study

• Viscosupplementation devices product providers
• Research organizations and consulting companies 
• Viscosupplementation devices -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in viscosupplementation devices 
• Various end-users who want to know more about the viscosupplementation devices market and the latest technological developments in the viscosupplementation devices market.  

Stay updated with us for Recent Articles @ New DelveInsight Blogs